Fast Company’s Top Ten In Biotech

01. Amyris
For deploying novel methods to fight an old foe, the malaria parasite (see page 102)

02. Omeros
For a new test to identify potential drug receptors

03. Synthetic Genomics
For its multi-application approach to synthetic microbes

04. Galapagos
For its super-efficient drug pipeline

05. Amgen
For a new osteoporosis drug that could also battle hormonal breast cancer

06. Fate Therapeutics
For devising an innovative way to test drugs on human cells

07. NovaBay
For antibiotic-like compounds that fight their battles by mimicking the human immune system

08. Oncogenex
For protein-targeting, chemo-boosting cancer treatments

09.  Myelin Repair Foundation
For its unorthodox, highly collaborative approach to drug development

10. Kane Biotech
For a wound-care spray that could aid and speed healing

Emeryville, Calif —  NovaBay Pharmaceuticals, Inc, a clinical stage biotechnology company developing anti-infective compounds for the
treatment and prevention of antibiotic-resistant infections, has been ranked seventh in the biotech industry in Fast Company magazine’s annual list of the world’s 50 most innovative companies in 2011.

The magazine praises NovaBay "for antibiotic-like compounds that fight their battles by mimicking the human immune system" in a list appearing in the March issue. The [removed]article[/removed] may also be accessed on the Fast Company website.

Commenting on how the selection process was conducted, Fast Company editors stated, "Our search for creative thinking, ingenious processes, and intelligent products took us deep into more than two dozen sectors and around the world. Our findings remind us of two things. First, that innovation can be found everywhere. And second, that some of the best ideas transcend sectors."

NovaBay’s Aganocide compounds are novel, synthetic N-chlorinated antimicrobial molecules specifically designed and developed to mimic
the body’s natural defense against infection. The Aganocide compounds maintain biological activities while demonstrating improved stability
over the naturally occurring N-chlorinated antimicrobial molecules. In a clinical study of 129 patients, NovaBay’s Aganocide compounds have
been shown to be highly effective against bacteria, including some multi-drug resistant strains (such as MRSA), viruses and fungi. These
compounds for topical treatment have the potential to deliver the same or better efficacy than antibiotics, and to address the growing problem
of antibiotic resistance by employing a novel mechanism of action.

Dr. Ron Najafi, chairman and CEO of NovaBay, said, "This high-profile recognition of our efforts is sincerely appreciated. There is a
substantial need for new solutions to the growing problem of antibiotic resistance, and innovative thinking is required for progress. We are proud that Fast Company has honored us in this way, and in doing so, it has shone a spotlight on our ongoing activities."

SOURCE: NovaBay Pharmaceuticals, Inc